Skip to main content
Advertisement
  • Loading metrics

Schistosomiasis Prevalence and Intensity of Infection in Latin America and the Caribbean Countries, 1942-2014: A Systematic Review in the Context of a Regional Elimination Goal

  • Ana Clara Zoni ,

    Contributed equally to this work with: Ana Clara Zoni, Laura Catalá, Steven K. Ault

    Affiliation Independent consultant, Madrid, Spain

  • Laura Catalá ,

    Contributed equally to this work with: Ana Clara Zoni, Laura Catalá, Steven K. Ault

    lcatalap@gmail.com; catalal@paho.org

    Affiliation Pan American Health Organization/World Health Organization, Washington, D.C., United States of America

  • Steven K. Ault

    Contributed equally to this work with: Ana Clara Zoni, Laura Catalá, Steven K. Ault

    Affiliation Pan American Health Organization/World Health Organization, Washington, D.C., United States of America

Abstract

Background

In 2012 the World Health Assembly adopted resolution WHA65.21 on elimination of schistosomiasis, calling for increased investment in schistosomiasis control and support for countries to initiate elimination programs. This study aims to analyze prevalence and intensity of Schistosoma mansoni infection in children in Latin America and the Caribbean countries and territories (LAC), at the second administrative level or lower.

Methodology

A systematic review of schistosomiasis prevalence and intensity of infection was conducted by searching at PubMed, LILACS and EMBASE. Experts on the topic were informally consulted and institutional web pages were reviewed (PAHO/WHO, Ministries of Health). Only SCH infection among children was registered because it can be a ‘proxi-indicator’ of recent transmission by the time the study is conducted.

Principal Findings

One hundred thirty two full-text articles met the inclusion criteria and provided 1,242 prevalence and 199 intensity of infection data points. Most of them were from Brazil (69.7%). Only Brazil published studies after 2001, showing several 'hot spots' with high prevalence. Brazil, Venezuela, Suriname and Saint Lucia need to update the epidemiological status of schistosomiasis to re-design their national programs and target the elimination of Schistosoma mansoni transmission by 2020. In Antigua and Barbuda, Dominican Republic, Guadeloupe, Martinique, Montserrat and Puerto Rico schistosomiasis transmission may be interrupted. However the compilation of an elimination dossier and follow-up surveys, per WHO recommendations, are needed to verify that status. Hence, the burden of subtle SCH chronic infection may be still present and even high in countries that may have eliminated transmission. Heterogeneity in the methodologies used for monitoring and evaluating the progress of the schistosomiasis programs was found, making cross-national and chronological comparisons difficult.

Conclusions

There is a need for updating the schistosomiasis status in the historically endemic countries and territories in LAC to address the required public health interventions for control and elimination programs or to verify the elimination of transmission of Schistosoma mansoni. Improved reporting and standardization of the monitoring and evaluation methodologies used are recommended, while using available WHO guidelines. Meeting a regional elimination goal will require additional and improved epidemiological data by age group and sex.

Author Summary

Schistosomiasis (Schistosoma spp) is an intestinal parasitic infection that causes anaemia, stunted growth, impaired cognition, and decreased physical fitness among other pathological effects. Currently, the control of schistosomiasis relies principally on mass drug administration of praziquantel. In addition, the implementation of further interventions such as snail (intermediate host) control, improving access to safe water and sanitation are required to achieve elimination of transmission in humans. An updated epidemiological situation will help countries to design tailor-made interventions enabling a step-up in prevention and control measures with the goal of elimination of transmission of this disease by 2020. In the region of the Americas, Schistosoma mansoni is the only species present that infect humans. This systematic review shows that in this region there is a need for re-mapping the schistosomiasis epidemiological situation in certain areas and countries in order to implement and optimize the best public health interventions needed to interrupt transmission or verify elimination of transmission. The methodology for monitoring and evaluating schistosomiasis control programs are well defined by current WHO guidelines. However, further investigations and guidelines on suitable tools for monitoring and evaluating schistosomiasis elimination programs and criteria and procedures for validating the elimination are required, and are currently being undertaken by WHO.

Introduction

Schistosomiasis (Schistosoma spp) is an infection caused by intestinal and urinary blood fluke parasites. Adult schistosome worms colonize human blood vessels for years,[1] eliminating eggs daily. The chronic infection can cause anemia, stunted growth, impaired cognition, decreased physical fitness, intestinal fibrosis veins, hepatosplenomegaly, neurological complications and death. Subsequently, this disease has a socioeconomic impact on the populations affected.[2,3] The highest prevalence and intensity of infection occur among children 10 to 14 years old.[3,4] Nevertheless, high prevalence and high intensity infections can be detected in pre school-age children (PSAC: 1–4 years old) and persist among adults.[5]

Over 200 million people are estimated to be infected and 700 million people are at risk of schistosomiasis infection globally.[68] There are mainly three species [2,9] that can infect humans, but Schistosoma mansoni (S. mansoni) is the only species present in Latin America and Caribbean countries and territories (LAC). In the S. mansoni endemic areas, the recommendation by WHO for monitoring and evaluation the control of schistosomiasis are the Kato-Katz coprological technique, wherein one can then calculate the arithmetic mean of the eggs per gram of stool (epg) and the severity levels of intensity of infection which are classified as: light (1–99 epg), moderate (100–499) epg, and heavy (500 epg or more).[10,11] Currently, the principle WHO-endorsed public health intervention in schistosomiasis-endemic areas are praziquantel-based (40 mg/kg according to prevalence infection) preventive chemotherapy (PC) depending on the schistosomiasis prevalence: prevalence below 10% once every three years, prevalence between 10% to 49% once every two years and prevalence of 50% or over once a year.[12] This should be accompanied by: snail host control, health education, hygiene promotion, access to safe water and sanitation improvement.[9,13]

In 2001, the World Health Assembly (WHA) set the target of treating with praziquantel at least 75% of school-age children (SAC: 5–14 years old) at risk of schistosomiasis infection by 2010.[14] Even though this target was not attained, in 2012 the WHA recognized the progress made and adopted resolution WHA65.21 on elimination of schistosomiasis, calling for increased investment in schistosomiasis control, and support for countries to initiate elimination programs, where appropriate. [13]. These resolutions are complemented by resolution CD49.R19 of the regional Directing Council of PAHO (2009), calling for a reduction to less than 10% in schistosomiasis prevalence and intensity of infection in high transmission zones by end of 2015.

In LAC, ten countries and territories are considered endemic by WHO. Over 1.6 million people are estimated to require preventive chemotherapy in Brazil and the Bolivarian Republic of Venezuela (hereafter referred to as Venezuela)[15]. Suriname and Saint Lucia may have residual transmission and the six additional countries and territories (Antigua and Barbuda, Guadeloupe, Martinique, Montserrat, Puerto Rico, Dominican Republic) may have eliminated the transmission, but these status need to be verify by compiling an elimination dossier and/or conducting epidemiological surveys.[16]

The objective is to compile data from a set of robust published epidemiological studies, which gives us a view of the prevalence and the intensity of S. mansoni infection in children in LAC, disaggregated to the second national administrative level (municipality) or lower.

Methods

A systematic review on schistosomiasis prevalence and intensity of infection among children in LAC was performed. Potentially relevant abstracts were identified in MEDLINE (PubMed), Embase, LILACS (including SciELO) and Cochrane Database of Systematic Reviews. Experts on the topic were consulted informally and institutional web pages were reviewed (PAHO/WHO, Ministries of Health).

The search terms used for research in PUBMED and EMBASE were: ‘‘Schistosomiasis”, ‘‘Child” as MeSH/Emtree terms and a mix of the names of all countries, capitals, and main cities of LAC as text terms. Additional qualifiers were used in PUBMED as MeSH search term “Epidemiology”, “Parasitology” OR “statistics” AND “numerical data”. In LILACS the keywords used were schistosomiasis AND (prevalence OR “intensity of infection”). Detailed information on the search terms and sources is provided online as Supplementary Material.

This review was conducted and reported in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Statement issued in 2009.[17]

The studies included in this review fulfilled the following criteria: (1) Studies published before April 30, 2014; (2) Studies carried out at the second administrative level (municipality) or lower (locality or neighborhood) in countries and territories from LAC; (3) Participants: children (≤19 years old) infected with S. mansoni; (4) Outcomes: prevalence and/or intensity of infection; (5) Study Design: randomized controlled trials (RCTs), systematic reviews, meta-analyses, cross sectional studies and observational studies. Only SCH infection among children was registered because it can be a ‘proxi-indicator’ of recent transmission by the time the study is conducted.

The excluded studies were those: (1) with sample size less than 30 participants; (2) involving adults that give aggregated results without the possibility of separately analyzing the results in children; (3) involving parasite species but do not report data for S. mansoni; (4) not published in Portuguese, French, Spanish or English; (5) which calculated prevalence by using clinical diagnosis exclusively; (6) in which the universe is hospital based; (7) with duplicated data.

Two reviewers independently (ACZ and LC) applied the inclusion and exclusion criteria to potential studies, with any disagreements resolved by discussion. For abstracts that met the inclusion criteria the full papers were assessed.

Data were registered based on schistosomiasis prevalence or intensity of infection per location, age groups for children (pre-SAC and SAC) and survey year. Thus, one citation could yield more than one record on the database.

From the extracted information in the database, descriptive analyses of the main findings were developed. Each value of prevalence and intensity of infection registered on the database was denominated a data point. Prevalence was categorized as follows: <1%, ≥1–9%, ≥10–49%, and ≥50%. The intensity of infection was registered as a geometric mean (GM), an arithmetic mean (AM) or unknown (U) when the authors did not report the method used, and the percentage of children by severity levels was also registered according to WHO classification or others.[10,11]

Statistical analysis and mapping were completed using Microsoft Excel, PASW (Predictive Analytics SoftWare) Statistics 18.0 and Tableau 8.2.

Results

The initial search identified a total of 842 citations. Most of these studies were excluded because they did not report prevalence or intensity of infection or were cases studies, leaving 241 studies for detailed screening. Of these, 109 were excluded mainly because they did not report outcomes in children. Agreement among the two reviewers was unanimous for the excluded citations. Fig 1 shows the flow diagram of the search, which was organized in accordance with the PRISMA guidelines. One hundred thirty two full-text articles met the inclusion criteria (Table 1) and these provided 1,242 prevalence and 199 intensity of infection data points.

thumbnail
Fig 1. Flow diagram of the systematic review according to PRISMA guidelines.

https://doi.org/10.1371/journal.pntd.0004493.g001

thumbnail
Table 1. Studies included in the systematic review and main characteristics.

https://doi.org/10.1371/journal.pntd.0004493.t001

A summary of the main methodological features of the studies included in the descriptive analysis is given in Table 2.

thumbnail
Table 2. Descriptive analysis of the main features of the articles included in the systematic review (N = 132).

https://doi.org/10.1371/journal.pntd.0004493.t002

Studies were identified for 9 of the 45 countries and territories of LAC; 2 from Latin America (Brazil and Venezuela) and 7 from the Caribbean (Dominican Republic, Guadeloupe, Martinique, Montserrat, Puerto Rico, Saint Lucia and Suriname) published between the 1st January 1942 and April 30, 2014. Even though an article from Antigua and Barbuda was identified, it was not included in the systematic review because it did not meet the inclusion criteria. The scientific literature mainly stemmed from Brazil (69.7%).

Most of the studies in the survey were conducted in the community compared to those that were conducted in schools, 65.2% vs. 34.8%, respectively. These were mainly concentrated in rural communities (57.8%). More than half of the studies did not report the sample methodology (66.9%) and did not analyze the results by sex (64.4%).

Sixty seven studies analyzed the intermediate host responsible for the transmission of schistosomiasis infection and the most frequent was the snail Biomphalaria glabrata (59.7%).

Heterogeneity in the diagnostic test used was found: 78.0% conducted solely a stool test and 15.9% combined and compared these with serological, dermatological and/or urinary tests. The Kato-Katz technique was the most used (55.6%).

Categorization according to age into two age groups, (PSAC, 1–4 years old and SAC, 5–14 years old) was performed in 36 articles (27.3%). The remaining articles addressed the analysis exclusively in SAC, with children of different ages (46.2%) or without disaggregating in age groups (9.1%), or created other classifications (17.4%).

All the included studies reported prevalence but only 33.3% (44 articles) reported the intensity of infection, being in 4 countries (Brazil, Dominican Republic, Saint Lucia and Suriname). Diversity was also observed in the way various authors quantified intensity of infection: most of the articles used a geometric mean (23.5%), followed by an arithmetic mean (5.3%). Only three articles (2.3%) from Brazil reported the levels of intensity of infection according to the categories of WHO.

Regarding the distribution of the prevalence points for S. mansoni data by countries, most were recorded for Brazil (727 points) and Puerto Rico (333 points). The remaining seven countries and territories generated a total of 184 prevalence data points.

In the entire study period the highest prevalence was observed by country as follows: in Brazil, in Minas Gerais for pre-SAC (62.5%) and in Pernambuco for SAC (94.6%); in Puerto Rico with higher values in Luquillo and Rio Grande (72.0% in SAC); in Guadeloupe in Basse-Terre (76.4% in SAC); in Saint Lucia in the region 5 (74.2% in SAC) and in Venezuela in Miranda (58.0%). The highest prevalence in the range of 10–49% were observed in: Martinique in Trinite (45.0% in SAC); in Dominican Republic in Hato Mayor (31.0% in SAC) and in Suriname in Saramacca (38.0% for all age group) and in the range of 1–9% in Montserrat in Saint George (5.0% in SAC). (Fig 2)

thumbnail
Fig 2. Prevalence of schistosomiasis infection in the Latin America and Caribbean countries and territories, 1942–2014.

https://doi.org/10.1371/journal.pntd.0004493.g002

Brazil was the only country with epidemiological studies done after 2001, which results were reported by age group for children. When these data were analyzed alone, several 'hot spots' with high prevalence (over 50%) and moderate in the upper limit of this range were observed (40–49%) in the states of Minas Gerais, Bahia and Pernambuco. (Table 3)

thumbnail
Table 3. Prevalence of schistosomiasis in children aged 1–15 years, Brazilian states.

Epidemiological surveys conducted between 2000 and 2010.

https://doi.org/10.1371/journal.pntd.0004493.t003

In relation to the intensity of infection, 153 out of a total of 199 data points were recorded for Brazil, distributed among eight states. Most of the records (73.7%) belonged to Pernambuco and Minas Gerais, and in these states the highest values were 630.0 epg and 796.4 epg, respectively. In three states (Alagoas, Bahia and Minas Gerais) 20–33% of the children were in the severe category of intensity of infection (over 500 epg). In Saint Lucia a total of 43 data points, covering region 5 (78.0 epg) and an area under national administration (13.0 to 72.0 epg) were recorded. In Dominican Republic only 2 data points were recorded in the province of La Altagracia (3.3 and 10.6 epg) and in Suriname 1 data point in the district of Saramacca (79.0 epg).

Discussion

This systematic review compiles 132 selected articles with 1,242 prevalence and 199 intensity of infection schistosomiasis data points about children in LAC, published between 1942 and 2014. A total of 9 LAC countries and territories identified as historically endemic areas for schistosomiasis were included.

Based on this review, we suggest the epidemiological status of the historically schistosomiasis endemic countries and territories in LAC needs to be updated, since the last published epidemiological surveys available were conducted: in the 1970s for Martinique, Guadeloupe and Montserrat; the 1980s for Dominican Republic and; the 1990s for Puerto Rico, Saint Lucia, Suriname and Venezuela. The only country with updated survey data in the scientific literature was Brazil, where high-prevalence states ('hot spots') were noted as Minas Gerais, Bahia and Pernambuco. The large number of universities and cohorts of MSc/PhD students concentrated in these populous states may explain the huge number of papers published. The unequal distribution of publications per country (and per state, within Brazil) and the outdated survey information also may reflect, in the worst case scenario, a) the difficulty that the countries face in publishing schistosomiasis data in indexed journals; b) the lack of human and economic resources to conduct epidemiological surveys; and/ or c) the lack of political will/interest for undertaking further surveys as the issue of schistosomiasis is often not considered a priority due to more pressing public health problems or the increasing relevance of other vector-borne diseases (e.g.; chikungunya). In the best case scenario, it may be indicative of interruption of transmission. However, also in these countries or foci where interruption of transmission in humans is suspected, epidemiological surveillance is key to prevent a recurrence of real clinical disease, especially in those countries (Guadeloupe and Brazil) where wild animals may have a role in maintaining transmission.[150,151] Furthermore, additional malacological and animal reservoir host studies might be necessary to design required SCH control and elimination strategies, including surveillance.[152,153] Recently, in collaboration with PAHO and/or other stakeholders some Ministers of Health conducted schistosomiasis surveys that are not yet published: Suriname in 2009/2010, Brazil in 2011/2014 and Dominican Republic in 2013. In order to move towards the verification of elimination of the schistosomiasis in humans it is key that these data and other un-published information are made available.

Despite the fact that Brazil has intensified efforts in schistosomiasis control, the results of the published surveys done after 2001 underscore that schistosomiasis continues to be transmitted in “hot spots” of high prevalence; the expansion of PC with praziquantel which Brazil is now undertaking in prioritized municipalities will benefit the affected population. Brazil and Venezuela reported 27,460 people treated with PC in 2012 (mainly in Brazil).[15] This Fig represented only 1.8% of the 1.6 million people estimated to require PC in the Americas. [15] Of the 5 schistosomiasis-endemic WHO regions requiring PC treatment globally, this WHO region with the lowest schistosomiasis PC coverage as reported for 2012, which could be explained by several reasons: (1) countries are not implementing PC strategies (either massive, targeted or focalized administration); (2) the information systems of the countries are not adapted to report individual versus PC mass treatments; and /or (3) health professionals do not record or support PC interventions. Whatever may be the possible reasons, health professionals should be aware that the public and individual health benefits of PC greatly outweigh the minimal risks which could arise.[12]

Only 44 articles, those from Brazil, Dominican Republic, Saint Lucia and Suriname, out of a total of 132 articles measured intensity of infection. Brazil was the country with the highest number of records of intensity of infection (153; 76.9%) and the only one which reported the percentage of children infected according to WHO’s intensity of infection classification levels.[10,11] The intensity of infection is one of the first indicators which is reduced when schistosomiasis PC is implemented. Therefore, it is very important to monitor the intensity of infection, because when intensity of infection is high it takes more time to reduce the prevalence and the post-treatment reinfections are more frequent. The intensity of infection was expressed as an arithmetic mean, as recommended by WHO, in only 9 articles; the geometric mean was the measure most used (31 articles), despite the fact that it can under- or overestimate the efficacy of praziquantel.[11] The classification by level of intensity of infection allows a quick assessment of the proportion of people who suffer from the serious consequences of this disease and therefore the burden of the disease in the community. Given the above, the draft guidelines for verification of elimination of schistosomiasis as proposed by WHO to control morbidity and to eliminate schistosomiasis as a public health problem established the goals to reach prevalence of severe intensity of infection of less than 5% and 1%, respectively. Therefore, schistosomiasis endemic countries need to assess the prevalence, but also measure intensity of infection, as recommended by WHO.[10]

This systematic review is focused on children to identify recent SCH transmission by the time the included studies were conducted. Therefore, this study may underestimate the prevalence of chronic schistosomiasis infection where transmission might be interrupted years ago but remains in adults and where results were not reported disaggregated by age group. For example, we have not included any data of the western focus in Venezuela (Chabasquen), which is in the confluence of Lara, Portuguesa and Trujillo states. This is an old focus still active, according to the Ministry of Health of Venezuela. [151]

The methodology for monitoring and evaluating schistosomiasis control programs are well defined by current WHO guidelines. However, further investigations and guidelines on suitable tools for monitoring and evaluating schistosomiasis elimination programs and criteria and procedures for validating the elimination of transmissions need to be published by WHO.

Even though there was a large variation in the ages of those surveyed and ways to classify age cohorts, SAC were the most analysed age group. This may be due to the following factors: (1) historically SAC have had the highest rates of SCH infection compared to PSAC or adults; (2) it is more difficult to survey pre-SAC than SAC; (3) the resolution WHA54.19 was aimed at minimum treatment for SAC but not for other age cohorts or groups; and/or (4) praziquantel was not available in paediatric solutions.[154] Nevertheless, new evidence in Africa reports rates in PSAC as high as those of SAC, thus the need for tackling schistosomiasis among this age group, as well.[155,156]

In conclusion, heterogeneity was detected in the methodologies used for the surveys and the way in which results were reported. Therefore, for future studies that attempt to update the epidemiological status, it is recommended that the following methodological suggestions be applied: (1) perform the analysis on children with a description of the results separate from the adult population because the absence of infections in this age group means interruption of transmission; (2) classify all children based on pre-SAC and SAC groups; (3) report the sample size; (4) describe whether the survey was conducted in the entire locality, and if not, what type of sampling was used; (5) specify the diagnostic test used, and if possible use the one recommended by WHO (Kato-Katz stool examination for schistosomiasis control programs); (6) analyze intensity of infection by an arithmetic mean; (7) report the percentage of children infected according to WHO’s intensity of infection classification levels. Additionally, given the scarce gender data on schistosomiasis infection, gender data should be collected.

To reach the elimination goal in the region of the Americas by 2020, there is need for updating the epidemiological status of some of the less-studied states in Brazil and in Venezuela, Suriname and Saint Lucia to address the required public health interventions, such as PC, snail control, improve access to safe water and sanitation, and promote health education. In the remaining countries and territories, evidence must be compiled to see whether interruption of schistosomiasis transmission has occurred.

Acknowledgments

We acknowledge the valuable inputs to this systematic review of the participants of the PAHO/WHO regional meeting on schistosomiasis elimination held in San Juan, Puerto Rico (October 2014) and colleagues of the Communicable Diseases and Health Analysis Department of the Pan American Health Organization/World Health Organization (particularly LGC and MIS). ACZ worked as a PAHO consultant for this review.

Author Contributions

Conceived and designed the experiments: ACZ LC SKA. Performed the experiments: ACZ LC. Analyzed the data: ACZ LC. Contributed reagents/materials/analysis tools: ACZ LC. Wrote the paper: ACZ LC SKA. Wrote the protocol of the systematic review, built the database, compiled and reviewed the studies selected for the systematic review, drafted the article: LC ACZ.

References

  1. 1. Vieira P, Miranda HP, Cerqueira M, Delgado ML, Coelho H, Antunes D, et al. Latent schistosomiasis in Portuguese soldiers. Mil Med. 2007; 172: 144–146. pmid:17357767
  2. 2. Colley DG, Bustinduy AL, Secor WE, King CH. Human schistosomiasis. Lancet. 2014; 383: 2253–2264. S0140-6736(13)61949-2 [pii]. pmid:24698483
  3. 3. DeStigter KV, King CH, Keating CE, Ouma JH, Siongok TK, Mahmoud AA. Effect of targeted mass treatment on intensity of infection and morbidity in schistosomiasis mansoni: seven-year follow-up of a community in Machakos, Kenya. Trans Assoc Am Physicians. 1989; 102: 209–212. pmid:2517855
  4. 4. King CH, Keating CE, Muruka JF, Ouma JH, Houser H, Siongok TK, et al. Urinary tract morbidity in schistosomiasis haematobia: associations with age and intensity of infection in an endemic area of Coast Province, Kenya. Am J Trop Med Hyg. 1988; 39: 361–368. pmid:3142286
  5. 5. Bustinduy AL, Parraga IM, Thomas CL, Mungai PL, Mutuku F, Muchiri EM, et al. Impact of polyparasitic infections on anemia and undernutrition among Kenyan children living in a Schistosoma haematobium-endemic area. Am J Trop Med Hyg. 2013; 88: 433–440. ajtmh.12-0552 [pii]. pmid:23324217
  6. 6. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380: 2163–2196. S0140-6736(12)61729-2 [pii]. pmid:23245607
  7. 7. Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J. Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect Dis. 2006; 6: 411–425. S1473-3099(06)70521-7 [pii]. pmid:16790382
  8. 8. Chitsulo L, Loverde P, Engels D. Schistosomiasis. Nat Rev Microbiol. 2004; 2: 12–13. pmid:15035004
  9. 9. Gryseels B, Polman K, Clerinx J, Kestens L. Human schistosomiasis. Lancet. 2006; 368: 1106–1118. S0140-6736(06)69440-3 [pii]. pmid:16997665
  10. 10. WHO. Helminth control in school age children: a guide for managers of control programmes. 2011
  11. 11. WHO. Assessing the efficacy of anthelminthic drugs against schistosomiasis and soil-transmitted helminthiases. 2013
  12. 12. WHO. Preventive chemotherapy in human helminthiasis: coordinated use of anthelminthic drugs in control interventions: a manual for health professionals and programme manage. 2006
  13. 13. WHO. Resolution WHA65.21. Elimination of schistosomiasis. Sixty-fifth World Health Assembly. 2012
  14. 14. WHO. Resolution WHA54.19. Schistosomiasis and soil-transmitted helminth infections. Fifty-fourth World Health Assembly. 2001
  15. 15. WHO. Schistosomiasis: number of people receiving preventive chemotherapy in 2012. Wkly Epidemiol Rec. 2014; 89: 21–28. pmid:24446558
  16. 16. PAHO. Report of the schistosomiasis regional meeting. Defining a road map towards verification of elimination of schistosomiasis transmission in the Latin America and the Caribbean countries by 2020. 2014
  17. 17. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009; 339: b2535. pmid:19622551
  18. 18. Amorim MN, Rabello A, Contreras RL, Katz N. Epidemiological characteristics of Schistosoma mansoni infection in rural and urban endemic areas of Minas Gerais, Brazil. Mem Inst Oswaldo Cruz. 1997; 92: 577–580. pmid:9566220
  19. 19. Artigas PT, Perez MD, Baggio D. [Coprological census in the Peruibe municipality (South shore line of the State of Sao Paulo). Record of autochthonous cases of Schistosomiasis mansoni]. Rev Saude Publica. 1969; 3: 141–147. pmid:5373773
  20. 20. Artigas PT, Perez MD, Otsuko JM, Nishimori G. [Parasitological survey, in particular of schistosomiasis mansoni, in Itanhaem and Mongagua cities (seacoast in the South of the State of Sao Paulo)]. Rev Saude Publica. 1970; 4: 35–44. pmid:5505835
  21. 21. Assis AM, Prado MS, Barreto ML, Reis MG, Conceicao Pinheiro SM, Parraga IM, et al. Childhood stunting in Northeast Brazil: the role of Schistosoma mansoni infection and inadequate dietary intake. Eur J Clin Nutr. 2004; 58: 1022–1029. pmid:15220944
  22. 22. Barbosa FS, Voss H. Evolution of the clinical gradient of Schistosoma mansoni infection in a small town in north-eastern Brazil. Bull World Health Organ. 1969; 40: 966–969. pmid:5307608
  23. 23. Barbosa FS, Pinto R, Souza OA. Control of schistosomiasis mansoni in a small north east Brazilian community. Trans R Soc Trop Med Hyg. 1971; 65: 206–213. pmid:5104969
  24. 24. Barbosa FS, Costa DP. A long-term schistosomiasis control project with molluscicide in a rural area of Brazil. Ann Trop Med Parasitol. 1981; 75: 41–52. pmid:7271354
  25. 25. Barbosa CS, Barbosa FS. [Schistosomiasis epidemiological patterns in a community of small farmers in Pernambuco State, Brazil]. Cad Saude Publica. 1998; 14: 129–137.
  26. 26. Barbosa CS, Pieri OS, da Silva CB, Barbosa FS. [Ecoepidemiology of urban schistosomiasis in Itamaraca Island, Pernambuco, Brazil]. Rev Saude Publica. 2000; 34: 337–341. S0034-89102000000400004 [pii]. pmid:10973151
  27. 27. Barbosa CS, Favre TC, Wanderley TN, Callou AC, Pieri OS. Assessment of schistosomiasis, through school surveys, in the Forest Zone of Pernambuco, Brazil. Mem Inst Oswaldo Cruz. 2006; 101 Suppl 1: 55–62. S0074-02762006000900009 [pii]. pmid:17308748
  28. 28. Barreto ML, Loureiro S. The effect of Schistosoma mansoni infection on child morbidity in the state of Bahia, Brazil. I—Analysis at the ecological level. Rev Inst Med Trop Sao Paulo. 1984; 26: 230–235. pmid:6522954
  29. 29. Barreto ML. Geographical and socioeconomic factors relating to the distribution of Schistosoma mansoni infection in an urban area of north-east Brazil. Bull World Health Organ. 1991; 69: 93–102. pmid:1905208
  30. 30. Bavia ME, Hale LF, Malone JB, Braud DH, Shane SM (1999) Geographic information systems and the environmental risk of schistosomiasis in Bahia, Brazil. Am J Trop Med Hyg 60: 566–572. pmid:10348229
  31. 31. Bethony J, Williams JT, Blangero J, Kloos H, Gazzinelli A, Soares-Filho B, et al. Additive host genetic factors influence fecal egg excretion rates during Schistosoma mansoni infection in a rural area in Brazil. Am J Trop Med Hyg. 2002; 67: 336–343. pmid:12452486
  32. 32. Bina JC, Prata A. An attempt to control schistosomiasis mansoni in an endemic area by the use of hycarrthone as chemotherapeutic agent. Rev Soc Brasil Med Trop. 1974; 8: 217–222.
  33. 33. Brito LL, Barreto ML, Silva RC, Assis AM, Reis MG, Parraga IM, et al. Moderate- and low-intensity co-infections by intestinal helminths and Schistosoma mansoni, dietary iron intake, and anemia in Brazilian children. Am J Trop Med Hyg. 2006; 75: 939–944. 75/5/939 [pii]. pmid:17123992
  34. 34. Burlandy-Soares LC, de Souza Dias LC, Kanamura HY, de Oliveira EJ, Ciaravolo RM. Schistosomiasis mansoni: follow-up of control program based on parasitologic and serologic methods in a Brazilian community of low endemicity. Mem Inst Oswaldo Cruz. 2003; 98: 853–859. S0074-02762003000600025 [pii]. pmid:14595468
  35. 35. Camargo-Neves VL, Kanamura HY, Vellosa SA, Gargioni C, Dias LC. IgM antibodies to Schistosoma mansoni gut-associated antigens for the study of schistosomiasis transmission in Ribeirao Pires, Sao Paulo. Mem Inst Oswaldo Cruz. 1998; 93 Suppl 1: 273–278. pmid:9921369
  36. 36. Carvalho OS, Rocha RS, Massara CL, Katz N. [Spread of schistosomiasis mansoni in Minas Gerais]. Mem Inst Oswaldo Cruz. 1987; 82 Suppl 4: 295–298. S0074-02761987000800056 [pii]. pmid:3151106
  37. 37. Carvalho OS, Massara CL, Silveira Neto HV, Alvarenga AG, Vidigal TH, Guerra HL, et al. Schistosomiasis mansoni in the region of the Triangulo Mineiro, State of Minas Gerais, Brazil. Mem Inst Oswaldo Cruz. 1994; 89: 509–512. S0074-02761994000400003 [pii]. pmid:8524054
  38. 38. Carvalho OS, Massara CL, Silveira Neto HV, Guerra HL, Caldeira RL, Mendonca CL, et al. Re-evaluation of schistosomiasis mansoni in Minas Gerais, Brazil—II. Alto Paranaiba mesoregion. Mem Inst Oswaldo Cruz. 1997; 92: 141–142.
  39. 39. Carvalho OS, Massara CL, Guerra HL, Campos YR, Caldeira RL, Chaves A, et al. Re-evaluation of schistosomiasis mansoni in Minas Gerais, Brazil. III. "Noroeste de Minas" mesoregion. Rev Inst Med Trop Sao Paulo. 1998; 40: 277–279. pmid:10030070
  40. 40. Cotta E, de Andrade RM. [Schistosomiasis mansoni in Belo Horizonte, MG(Brazil). Former and current status of this problem]. Rev Bras Malariol Doencas Trop. 1967; 19: 161–184. pmid:5613530
  41. 41. Coura JR, Conceicao MJ, Pereira JB. [Morbidity of schistosomiasis mansoni in Brazil. Developmental study in an endemic area over a 10-year period]. Mem Inst Oswaldo Cruz. 1984; 79: 447–453. S0074-02761984000400009 [pii]. pmid:6335910
  42. 42. Coura JR, Mendonca N, Madruga JP. Evaluation of a special program for the control of schistosomiasis (PECE) in Paraíba State, Brazil. Rev Soc Brasil Med Trop. 1987; 20: 67–76.
  43. 43. Coura JR, Conceicao J, dos Santos ML, de Mendonca ZG, Cutrim RN.; Cross-sectional and evolutive studies of schistosomiasis mansoni in untreated and mass treated endemic areas in the southeast and northeast of Brazil. Mem Inst Oswaldo Cruz. 1992; 87 Suppl 4: 175–182. S0074-02761992000800027 [pii]. pmid:1343891
  44. 44. Coura FP, Rocha RS, de Lima e Costa MF, Katz N. A municipal level approach to the management of schistosomiasis control in Peri-Peri, MG, Brazil. Rev Inst Med Trop Sao Paulo. 1992; 34: 543–548. pmid:1342123
  45. 45. Coura-Filho P, Rocha RS, Farah MW, da Silva GC, Katz N. Identification of factors and groups at risk of infection with Schistosoma mansoni: a strategy for the implementation of control measures? Rev Inst Med Trop Sao Paulo. 1994; 36: 245–253. pmid:7855489
  46. 46. Coura-Filho P, Farah MW, Rezende DF, Lamartine SS, Carvalho OS, Katz N. [Environmental and social determinants in schistosomiasis mansoni in Ravena, Minas Gerais, Brazil]. Cad Saude Publica. 1995; 11: 254–265. S0102-311X1995000200009 [pii]. pmid:14528332
  47. 47. Coura-Filho P, Rocha RS, Lamartine SS, Farah MW, de Resende DF, Costa JO, et al. Control of schistosomiasis mansoni in Ravena (Sabara, state of Minas Gerais, Brazil) through water supply and quadrennial treatments. Mem Inst Oswaldo Cruz. 1996; 91: 659–664. pmid:9283641
  48. 48. Coura-Filho P. [An alternative model for schistosomiasis control with active participation by the population through the Unified Health System (SUS) in Taquaracu de Minas (Minas Gerais, Brazil) from 1985 to 1995]. Cad Saude Publica. 1998; 14 Suppl 2: 111–122. pmid:9700230
  49. 49. Cury GC, Salles PG, Reis MC, Rego VM, Arndt AW, de Souza Filho CB, et al. [Prevalence of schistosomiasis mansoni and parasitic intestinal diseases among students of the rural area of the Municipality of Jaboticatubas, MG, 1992–1993]. Rev Soc Bras Med Trop. 1994; 27: 217–220. pmid:7855363
  50. 50. Cutrim RN, Chieffi PP, de Moraes JC. Schistosomiasis mansoni in the "Baixada Ocidental Maranhense", state of Maranhao, Brazil: cross-sectional studies performed in 1987 and 1993. Rev Inst Med Trop Sao Paulo.1998; 40: 165–171. pmid:9830730
  51. 51. da Costa DP, Barbosa FS. [Schistosomiasis in workers of the Catende Sugar Mill, Pernambuco, Brazil]. Rev Saude Publica. 1980; 14: 469–474. pmid:7268291
  52. 52. da Silva AA, Cutrim RN, de Britto e Alves MT, Coimbra LC, Tonial SR, Borges DP. Water-contact patterns and risk factors for Schistosoma mansoni infection in a rural village of northeast Brazil. Rev Inst Med Trop Sao Paulo. 1997; 39: 91–96. pmid:9394521
  53. 53. de Lima e Costa MF, Rocha RS, Zicker F, Katz N. Evolution of schistosomiasis in an hyperendemic area of the Minas Gerais State: two cross-sectional studies. Rev Inst Med Trop Sao Paulo.1985; 27: 279–285. pmid:3938861
  54. 54. de Souza Gomes EC, Leal-Neto OB, de O Jr., Campos JV, Souza-Santos R, Barbosa CS Risk analysis for occurrences of schistosomiasis in the coastal area of Porto de Galinhas, Pernambuco, Brazil. BMC Infect Dis. 2014; 14.
  55. 55. De Vlas SJ, Engels D, Rabello AL, Oostburg BF, Van LL, Polderman AM, et al. Validation of a chart to estimate true Schistosoma mansoni prevalences from simple egg counts. Parasitology. 1997; 114 (Pt 2): 113–121. pmid:9051920
  56. 56. Dias E. [Preliminary study of schistosomiasis mansoni in Bambua county, State of Minas Gerais]. Rev Bras Malariol Doencas Trop. 1953; 5: 211–215. pmid:13134726
  57. 57. Disch J, Garcia MM, Krijger GW, Amorim MN, Katz N, Deelder AM, et al. Daily fluctuation of levels of circulating cathodic antigen in urine of children infected with Schistosoma mansoni in Brazil. Trans R Soc Trop Med Hyg. 1997; 91: 222–225. pmid:9196777
  58. 58. Enk MJ, Lima AC, Drummond SC, Schall VT, Coelho PM. The effect of the number of stool samples on the observed prevalence and the infection intensity with Schistosoma mansoni among a population in an area of low transmission. Acta Trop. 2008; 108: 222–228. S0001-706X(08)00262-3 [pii]. pmid:18973744
  59. 59. Enk MJ, Lima AC, Barros HS, Massara CL, Coelho PM, Schall VT. Factors related to transmission of and infection with Schistosoma mansoni in a village in the South-eastern Region of Brazil. Mem Inst Oswaldo Cruz. 2010; 105: 570–577. S0074-02762010000400037 [pii]. pmid:20721510
  60. 60. Fleming FM, Brooker S, Geiger SM, Caldas IR, Correa-Oliveira R, Hotez PJ, et al. Synergistic associations between hookworm and other helminth species in a rural community in Brazil. Trop Med Int Health. 2006; 11: 56–64. TMI1541 [pii]. pmid:16398756
  61. 61. Fontes G, Oliveira KK, Oliveira AK, da Rocha EM. [Influence of specific treatment of intestinal parasites and schistosomiasis on prevalence in students in Barra de Santo Antonio, AL]. Rev Soc Bras Med Trop. 2003; 36: 625–628. S0037-86822003000500015 [pii]. pmid:14576880
  62. 62. Favre TC, Pereira AP, Galvao AF, Zani LC, Barbosa CS, Pieri OS. A rationale for schistosomiasis control in elementary schools of the rainforest zone of pernambuco, Brazil. PLoS Negl Trop Dis. 2009; 3: e395. pmid:19290040
  63. 63. Froes E, Piza JT, Ramos AdS, Dias LC, Pinto AC. [Epidemiologic and preventive aspects of schistosomiasis Mansoni in San Jose de Campos]. Hospital (Rio J). 1970; 77: 1587–1598.
  64. 64. Galvao AF, Favre TC, Guimaraes RJ, Pereira AP, Zani LC, Felipe KT, et al. Spatial distribution of Schistosoma mansoni infection before and after chemotherapy with two praziquantel doses in a community of Pernambuco, Brazil. Mem Inst Oswaldo Cruz. 2010; 105: 555–562. S0074-02762010000400035 [pii]. pmid:20721508
  65. 65. Gazzinelli A, Velasquez-Melendez G, Crawford SB, Loverde PT, Correa-Oliveira R, Kloos H Socioeconomic determinants of schistosomiasis in a poor rural area in Brazil. Acta Trop. 2006; 99: 260–271. S0001-706X(06)00151-3 [pii]. pmid:17045559
  66. 66. Gazzinelli MF, Reis DC, Kloos H, Velasquez-Melendez G, Dutra IR, Gazzinelli A. The impact of two education methods on knowledge of schistosomiasis transmission and prevention among schoolchildren in a rural community in northern Minas Gerais, Brazil. Mem Inst Oswaldo Cruz. 2006; 101 Suppl 1: 45–53. S0074-02762006000900008 [pii]. pmid:17308747
  67. 67. Goncalves MM, Barreto MM, Maldonado A Jr., Maione VR, Rey L, Soares MS. [Socio-cultural and ethical factors involved in the diagnosis of schistosomiasis mansoni in an area of low endemicity]. Cad Saude Publica. 2005; 21: 92–100. S0102-311X2005000100011 [pii];. pmid:15692642
  68. 68. Grault CE, Mello-Silva CC, Costa MJ, Lenzi MF, Cruz OJ, Almeida AS, et al. Potential spread of schistosomiasis in the periphery of greater metropolitan region of Rio de Janeiro. Mem Inst Oswaldo Cruz. 1998; 93 Suppl 1: 293–294. pmid:9921373
  69. 69. Guimaraes MD, Costa MF, de Lima LB, Moreira MA. [Clinico-epidemiological study of schistosomiasis mansoni in school children of Ilha, municipality of Arcos, MG (Brazil) 1983]. Rev Saude Publica. 1985; 19: 8–17. pmid:3936161
  70. 70. Guimaraes MD, de Barros HL, Katz N. A clinical epidemiologic study in a schistosomiasis mansoni endemic area (Tuparece, Minas Gerais). Rev Inst Med Trop Sao Paulo. 1985; 27: 123–131. pmid:3938062
  71. 71. Guimaraes RJ, Freitas CC, Dutra LV, Moura AC, Amaral RS, Drummond SC, et al. Analysis and estimative of schistosomiasis prevalence for the state of Minas Gerais, Brazil, using multiple regression with social and environmental spatial data. Mem Inst Oswaldo Cruz. 2006; 101 Suppl 1: 91–96. S0074-02762006000900014 [pii]. pmid:17308753
  72. 72. Kanamura HY, Dias LC, Glasser CM, Da Silva RM, Patucci RM, Chiodelli SG, et al. Detection of IgM antibodies to Schistosoma mansoni gut-associated antigens for the study of the dynamics of schistosomiasis transmission in an endemic area with low worm burden. Rev Inst Med Trop Sao Paulo. 1998; 40: 225–231. pmid:9876435
  73. 73. Kanamura HY, Dias LC, Da Silva RM, Glasser CM, Patucci RM, Vellosa SA, et al. A comparative epidemiologic study of specific antibodies (IgM and IgA) and parasitological findings in an endemic area of low transmission of schistosoma mansoni. Rev Inst Med Trop Sao Paulo. 1998; 40: 85–91. pmid:9755561
  74. 74. Katz N, Carvalho OS. [Recent introduction of schistosomiasis mansoni into the south of the State of Minas Gerais, Brazil]. Mem Inst Oswaldo Cruz. 1983; 78: 281–284. S0074-02761983000300006 [pii]. pmid:6656599
  75. 75. Kawazoe U, Hoshino-Shimizu S, Correa NS, Silva LC, Pinto AC, Camargo ME. An immunoepidemiological study of schistosomiasis mansoni in Paraiba's Valley, Sao Paulo, Brazil. Rev Inst Med Trop Sao Paulo. 1981; 23: 36–40. pmid:7025165
  76. 76. Kloetzel K, Schuster NH. Repeated mass treatment of schistosomiasis mansoni: experience in hyperendemic areas of Brazil. I. Parasitological effects and morbidity. Trans R Soc Trop Med Hyg. 1987; 81: 365–370. pmid:3120363
  77. 77. Kloetzel K. Some personal views on the control of schistosomiasis mansoni. Mem Inst Oswaldo Cruz. 1992; 87 Suppl 4: 221–226. S0074-02761992000800034 [pii]. pmid:1343899
  78. 78. Lambertucci JR, Gerspacher-Lara R, Pinto-Silva RA, Barbosa MM, Teixeira R, Barbosa HF, et al. [The Queixadinha Project: morbidity and control of schistosomiasis in an endemic area in the northeast of Minas Gerais, Brazil]. Rev Soc Bras Med Trop. 1996; 29: 127–135. pmid:8713604
  79. 79. Lambertucci JR, Cota GF, Pinto-Silva RA, Serufo JC, Gerspacher-Lara R, Costa DS, et al. Hepatosplenic schistosomiasis in field-based studies: a combined clinical and sonographic definition. Mem Inst Oswaldo Cruz. 2001; 96 Suppl: 147–150. S0074-02762001000900022 [pii]. pmid:11586441
  80. 80. Leal Neto OB, Galvao TY, Esteves FA, Gomes AM, Gomes EC, de Araujo KC, et al. Spatial analysis of schistosomiasis human cases in the horticultural community of Zona da Mata of Pernambuco state, Brazil. Rev Bras Epidemiol. 2012; 15: 771–780. S1415-790X2012000400009 [pii]. pmid:23515773
  81. 81. Lehman JS Jr., Mott KE, Morrow RH Jr., Muniz TM, Boyer MH. The intensity and effects of infection with Schistosoma mansoni in a rural community in northeast Brazil. Am J Trop Med Hyg. 1976; 25: 285–294. pmid:1259089
  82. 82. Lima e Costa MF, Guerra HL, Pimenta FG Jr., Firmo JO, Uchoa E. [Evaluation of a program for the control of schistosomiasis in municipalities located on the basin of the Sao Francisco River, Minas Gerais, Brazil]. Rev Soc Bras Med Trop. 1996; 29: 117–126. pmid:8713603
  83. 83. Lima VL, Guercio VM, Rangel O, Kanamura HY, Dias LC. Immunofluorescence test on Schistosoma mansoni worm paraffin sections (IgM-IFT) for the study of schistosomiasis transmission in Campinas, Sao Paulo, Brazil. Mem Inst Oswaldo Cruz. 1998; 93 Suppl 1: 283–287. pmid:9921371
  84. 84. Marcal JO, Patucci RM, Dias LC, Hotta LK, Etzel A. Schistosomiasis mansoni in an area of low transmission. I. Impact of control measures. Rev Inst Med Trop Sao Paulo. 1991; 33: 83–90. pmid:1844388
  85. 85. Massara CL, Peixoto SV, Barros HS, Enk MJ, Carvalho OS, Schall V. Factors associated with schistosomiasis mansoni in a population from the municipality of Jaboticatubas, State of Minas Gerais, Brazil. Mem Inst Oswaldo Cruz. 2004; 99: 127–134. S0074-02762004000900023 [pii];.
  86. 86. Melo JE, Cutrim RN, Bulcao JR, de Araujo JP. [Prevalence of the principle helminthiases in the State of Maranhao, Brazil]. Rev Bras Malariol Doencas Trop. 1983; 35: 65–71. pmid:6334334
  87. 87. Mota E, Sleigh AC. Water-contact patterns and Schistosoma mansoni infection in a rural community in northeast Brazil. Rev Inst Med Trop Sao Paulo. 1987; 29: 1–8. pmid:3114861
  88. 88. Moza PG, Pieri OS, Barbosa CS, Rey L. [Sociodemographic and behavioral factors related to schistosomiasis in a rural village of the sugar cane belt in Pernambuco State, Brazil]. Cad Saude Publica. 1998; 14: 107–115. pmid:9592216
  89. 89. Olliaro PL, Vaillant MT, Belizario VJ, Lwambo NJ, Ouldabdallahi M, Pieri OS, et al. A multicentre randomized controlled trial of the efficacy and safety of single-dose praziquantel at 40 mg/kg vs. 60 mg/kg for treating intestinal schistosomiasis in the Philippines, Mauritania, Tanzania and Brazil. PLoS Negl Trop Dis. 2011; 5: e1165. pmid:21695161
  90. 90. Palmeira DC, Carvalho AG, Rodrigues K, Couto JL. [Prevalence of Schistosoma mansoni infection in two municipalities of the State of Alagoas, Brazil]. Rev Soc Bras Med Trop. 2010; 43: 313–317. S0037-86822010000300020 [pii]. pmid:20563503
  91. 91. Paraense WL, de Alencar JT, Correa LR. [Planorbid distribution and the prevalence of schistosomiasis mansoni in the State of Espirito Santo]. Mem Inst Oswaldo Cruz. 1983; 78: 373–384. S0074-02761983000300013 [pii]. pmid:6606755
  92. 92. Paredes H, Souza-Santos R, Resendes AP, Souza MA, Albuquerque J, Bocanegra S, et al. Spatial pattern, water use and risk levels associated with the transmission of schistosomiasis on the north coast of Pernambuco, Brazil. Cad Saude Publica. 2010; 26: 1013–1023. S0102-311X2010000500023 [pii]. pmid:20563401
  93. 93. Paulini E, Dias EP. [Results of 3 years of schistosomiasis control in Belo Horizonte (MG)]. Rev Bras Malariol Doencas Trop. 1971; 23: 151–172. pmid:5162370
  94. 94. Pereira LF, Gazzaneo AL, Melo RM, Tenorio HC, Oliveira DS, Alves MS, et al. Clinical and laboratory evaluation of schistosomiasis mansoni patients in Brazilian endemic areas. Mem Inst Oswaldo Cruz. 2010; 105: 449–453. S0074-02762010000400016 [pii]. pmid:20721489
  95. 95. Pereira C. Occcurence of shistosomiasis and the others intestinal parasites in children and teenager of a public school in Jequié, Bahia, Brasil. Rev Saúde Com. 2010; 6: 24–30.
  96. 96. Pereira WR, Kloos H, Crawford SB, Velasquez-Melendez JG, Matoso LF, Fujiwara RT, et al. Schistosoma mansoni infection in a rural area of the Jequitinhonha Valley, Minas Gerais, Brazil: analysis of exposure risk. Acta Trop. 2010; 113: 34–41. S0001-706X(09)00282-4 [pii]. pmid:19765542
  97. 97. Perez MD, Hyakutake S, Areas JA, Filho FF. [Parasitological survey, with special reference to schistosomiasis mansoni, conducted in the region of Jacupiranga (Ribeira valley, State of Sao Paulo). Survey of the location and distribution of planorbidian snails in the State of Sao Paulo. VII]. Rev Farm Bioquim Univ Sao Paulo. 1975; 13: 401–415. pmid:1241922
  98. 98. Pieri OS, Barbosa CS, Moza PG. Schistosomiasis control based on repeated chemotherapy in a rural village of the sugar-cane zone in northeast Brazil. Mem Inst Oswaldo Cruz. 1998; 93 Suppl 1: 259–264. pmid:9921364
  99. 99. Rocha RS, Silva JG, Peixoto SV, Caldeira RL, Firmo JO, Carvalho Od, et al. [Assessment of schistosomiasis and other intestinal parasitoses in school children of the Bambui municipality, Minas Gerais, Brazil]. Rev Soc Bras Med Trop. 2000; 33: 431–436. pmid:11064579
  100. 100. Rodrigues RN, Murta C, Teixeira Junior MA, Cury GC, Rocha MO. Clinical-epidemiologic study of schistosomiasis mansoni in Ponte do Pasmado, a village in the municipality of Itinga, state of Minas Gerais, Brazil, 1992. Rev Inst Med Trop Sao Paulo. 1995; 37: 81–85. pmid:7569646
  101. 101. Rodrigues LC, Wheeler JG, Shier R, Guerra HL, Pimenta F Jr., Lima eCosta MF. Predicting the community prevalence of schistosomiasis mansoni from the prevalence among 7- to 14-year-olds. Parasitology. 2000; 121 Pt 5: 507–512. pmid:11128802
  102. 102. Santana VS, Teixeira MG, Santos CC. [Control of schistosomiasis infection in the localities of Cachoeira-Bahia, basin of the Paraguacu, 1982–1992]. Rev Soc Bras Med Trop. 1996; 29: 185–195. pmid:8713610
  103. 103. Santana VS, Teixeira MG, Santos CP, de Andrade CA. [The effectiveness of the Program of Communication and Education in Health on the control of S. mansoni infection in some areas of the state of Bahia]. Rev Soc Bras Med Trop. 1997; 30: 447–456. pmid:9463191
  104. 104. Schall VT, Dias AG, Malaquias ML, Dos Santos MG. [Health education in 1st grade public schools at the periphery of Belo Horizonte, MG, Brazil. I. Evaluation of the program relative to schistosomiasis]. Rev Inst Med Trop Sao Paulo. 1993; 35: 563–572. pmid:7997762
  105. 105. Tanabe M, Goncalves JF, Goncalves FJ, Tateno S, Takeuchi T. Occurrence of a community with high morbidity associated with Schistosoma mansoni infection regardless of low infection intensity in north-east Brazil. Trans R Soc Trop Med Hyg. 1997; 91: 144–149. pmid:9196752
  106. 106. Vasconcelos CH, Cardoso PC, Quirino WC, Massara CL, Amaral GL, Cordeiro R, et al. [Evaluation of schistosomiasis mansoni control measures in Sabara, Minas Gerais State, Brazil, 1980–2007]. Cad Saude Publica. 2009; 25: 997–1006. S0102-311X2009000500006 [pii].
  107. 107. Vinha C. [The incidence of schistosomiasis in the State of Rio Grande do Norte]. Rev Bras Malariol Doencas Trop. 1968; 20: 3–37. pmid:5701047
  108. 108. Ximenes R, Southgate B, Smith PG, Guimaraes NL. Socioeconomic determinants of schistosomiasis in an urban area in the Northeast of Brazil. Rev Panam Salud Publica. 2003; 14: 409–421. S1020-49892003001100006 [pii]. pmid:14769158
  109. 109. Zacharias F, de Carvalho ME, Gargioni C, Teles HM, Ferreira CS, de Lima VR. Schistosomiasis mansoni in Bananal (State of Sao Paulo, Brazil): III. Seroepidemiological studies in the Palha District. Mem Inst Oswaldo Cruz. 2002; 97 Suppl 1: 19–22. S0074-02762002000900005 [pii]. pmid:12426588
  110. 110. Hillyer GV. Schistosomiasis in the Dominican Republic: a review. Bol Asoc Med P R. 1983; 75: 114–117. pmid:6351874
  111. 111. Mota-Chala I, Alvarez-Santana DA, Linche-Mota DT, Ventura-Lopez E, Santana-Palacio JJ, Encarnacion A. Schistosomiasis in endemic areas in the eastern region of Dominican Republic. Rev Med Dom. 1995; 56: 18–19.
  112. 112. Read H. [New concepts on schistosomiasis in Santo Domingo]. Prensa Med Argent 1966; 53: 887–890. pmid:4881853
  113. 113. Vargas M, Gomez PJ, Malek EA. Schistosomiasis mansoni in the Dominican Republic; prevalence and intensity in the city of Higuey by coprological and serological methods. Trop Geogr Med. 1987; 39: 244–250. pmid:3124312
  114. 114. WHO. Atlas of the global distribution of schistosomiasis: Dominican Republic-Puerto Rico. 1987
  115. 115. Lapierre J, Floch HA, Holler C, Saison E. [Distribution of intestinal schistosomiasis in Guadeloupe: sero-immunologic survey by immunofluorescence (1st trial)]. Bull Soc Pathol Exot Filiales. 1972; 65: 434–437. pmid:4569980
  116. 116. WHO. Atlas of the global distribution of schistosomiasis: Guadeloupe. 1987
  117. 117. WHO. Atlas of the global distribution of schistosomiasis: Martinique. 1987
  118. 118. Tikasingh ES, Wooding CD, Long E, Lee CP, Edwards C. The presence of Schistosoma mansoni in Montserrat Leeward Islands. J Trop Med Hyg. 1982; 85: 41–43. pmid:6978409
  119. 119. Palmer JR, Colon AZ, Ferguson FF, Jobin WR. The control of schistosomiasis in Patillas, Puerto Rico. Public Health Rep. 1969; 84: 1003–1007. pmid:4982247
  120. 120. Ferguson FF. Occurrence of schistosoma mansoni in puerto ricans. Public Health Rep. 1965; 80: 339–344. pmid:14279979
  121. 121. Ferguson FF, Palmer JR, Jobin WR. Control of schistosomiasis on Vieques Island, Puerto Rico. Am J Trop Med Hyg. 1968; 17: 858–863. pmid:5749745
  122. 122. Giboda M, Malek EA, Correa R. Human schistosomiasis in Puerto Rico: Reduced prevalence rate and absence of Biomphalaria glabrata. Am J Trop Med Hyg. 1997; 57: 564–568. pmid:9392596
  123. 123. Hiatt RA, Cline BL, Knight WB. Limitations of the intradermal test for schistosomiasis mansoni: experience from epidemiologic studies in a Puerto Rican community. Am J Trop Med Hyg. 1978; 27: 535–541. pmid:677365
  124. 124. Hiatt RA, Cline BL, Ruiz-Tiben E, Knight WB, Berrios-Duran LA. The Boqueron Project after 5 years: a prospective community-based study of infection with Schistosoma mansoni in Puerto Rico. Am J Trop Med Hyg. 1980; 29: 1228–1240. pmid:7446813
  125. 125. Hillyer GV, Tsang VC, Vivas-Gonzalez BE, Noh J, Ahn LH, Vorndam V. Age-specific decrease in seroprevalence of schistosomiasis in Puerto Rico. Am J Trop Med Hyg. 1999; 60: 313–318. pmid:10072158
  126. 126. Jobin WR, Ruiz-Tiben E. Bilharzia and patterns of human contact with water in Puerto Rico. Bol Asoc Med P R. 1968; 60: 279–284. pmid:5249667
  127. 127. Jobin WR, Ferguson FF, Palmer JR. Control of schistosomiasis in Guayama and Arroyo, Puerto Rico. Bull World Health Organ. 1970; 42: 151–156. pmid:5309511
  128. 128. Maldonado JF, Oliver-Gonzalez J. The prevalence of Schistosoma mansoni in certain localities of Puerto Rico: a three year study. Am J Trop Med Hyg. 1958; 7: 386–391. pmid:13559588
  129. 129. Negron AH, Ramos-Morales F, Jobin WR. Field trial in Ceiba Norte of epidemiological tests for operational evaluation of schistosomiasis control in Puerto Rico. Bol Asoc Med P R. 1978; 70: 298–307. pmid:358998
  130. 130. Negron-Aponte H, Maria NC. The 1976 skin test survey for schistosomiasis in Puerto Rico. Bol Asoc Med P R. 1979; 71: 17–25. pmid:284785
  131. 131. Negron-Aponte H, Jobin WR. Schistosomiasis control in Puerto Rico: twenty-five years of operational experience. Am J Trop Med Hyg. 1979; 28: 515–525. pmid:453447
  132. 132. Tiben ER, Cox PM Jr., Clark WD, Greenberg ER. The 1969 schistosomiasis skin test survey in Puerto Rico. Bol Asoc Med P R. 1973; 65: 170–173. pmid:4531920
  133. 133. White PC Jr., Pimentel D, Garcia FC. Distribution and prevalence of human schistosomiasis in Puerto Rico in 1953. Am J Trop Med Hyg. 1957; 6: 715–726. pmid:13458682
  134. 134. Barnish G, Jordan P, Bartholomew RK, Grist E. Routine focal mollusciciding after chemotherapy to control Schistosoma mansoni in Cul de Sac valley, Saint Lucia. Trans R Soc Trop Med Hyg. 1982; 76: 602–609. pmid:7179412
  135. 135. Bartholomew RK, Peters PA, Jordan P. Schistosoma mansoni in St. Lucian and Kenyan communities—a comparative study using the Kato stool examination technique. Ann Trop Med Parasitol. 1981; 75: 401–405. pmid:7305508
  136. 136. Cook JA, Jordan P, Bartholomew RK. Control of Schistosoma mansoni transmission by chemotherapy in St. Lucia. I. Results in man. Am J Trop Med Hyg. 1977; 26: 887–893. pmid:907051
  137. 137. Jordan P, Woodstock L, Unrau GO, Cook JA. Control of Schistosoma mansoni transmission by provision of domestic water supplies. A preliminary report of a study in St Lucia. Bull World Health Organ. 1975; 52: 9–20. pmid:1082384
  138. 138. Jordan P, Woodstock L, Cook JA. Preliminary parasitological results of a pilot mollusciciding campaign to control transmission of Schistosoma mansoni in St Lucia. Bull World Health Organ. 1976; 54: 295–302. pmid:1088109
  139. 139. Jordan P, Cook JA, Bartholomew RK, Grist E, Auguste E. Schistosoma mansoni control in Cul de Sac Valley, Saint Lucia. II. Chemotherapy as a supplement to a focal mollusciciding programme. Trans R Soc Trop Med Hyg. 1980; 74: 493–500. pmid:7445046
  140. 140. Jordan P, Bartholomew RK, Grist E, Auguste E. Evaluation of chemotherapy in the control of Schistosoma mansoni in Marquis Valley, Saint Lucia. I. Results in humans. Am J Trop Med Hyg. 1982; 31: 103–110. pmid:7058971
  141. 141. Jordan P, Unrau GO, Bartholomew RK, Cook JA, Grist E. Value of individual household water supplies in the maintenance phase of a schistosomiasis control programme in Saint-Lucia, after chemotherapy. Bull World Health Organ. 1982; 60: 583–588. pmid:6982781
  142. 142. Kurup R, Hunjan GS. Epidemiology and control of Schistosomiasis and other intestinal parasitic infections among school children in three rural villages of south Saint Lucia. J Vector Borne Dis. 2010; 47: 228–234. pmid:21178216
  143. 143. Prentice MA, Jordan P, Bartholomew RK, Grist E. Reduction in transmission of Schistosoma mansoni by a four-year focal mollusciciding programme against Biomphalaria glabrata in Saint Lucia. Trans R Soc Trop Med Hyg. 1981; 75: 789–798. pmid:7330940
  144. 144. Prentice MA, Barnish G. Snail infections following chemotherapy of Schistosoma mansoni in St. Lucia, West Indies. Trans R Soc Trop Med Hyg. 1981; 75: 713–714. pmid:7330926
  145. 145. Van Der Kuup E. A local schistosomiasis explosion in Surinam. Trop Geogr Med. 1971; 23: 376–380. pmid:5173759
  146. 146. van der Kuyp E. Schistosomiasis mansoni in the Saramacca District of Surinam. Trop Geogr Med. 1969; 21: 88–92. pmid:5767537
  147. 147. Van LL, Panday UG, De JN, Krijger FW, Oostburg BF, Polderman AM, et al. Immunodiagnosis of schistosomiasis mansoni in a low endemic area in Surinam by determination of the circulating antigens CAA and CCA. Acta Trop. 1995; 59: 19–29. 0001706X9400084E [pii]. pmid:7785523
  148. 148. Alarcon De NB, Ruiz R, Losada S, Colmenares C, Contreras R, Cesari IM, et al. Detection of schistosomiasis cases in low-transmission areas based on coprologic and serologic criteria The Venezuelan experience. Acta Trop. 2007; 103: 41–49. S0001-706X(07)00126-X [pii]. pmid:17606217
  149. 149. Scott JA. The epidemiology of schistosomiasis in Venezuela. Am J Epidemiol. 1942; 35: 337–366.
  150. 150. Modena CM, dos Santos LW, Coelho PM. Wild and domesticated animals as reservoirs of Schistosomiasis mansoni in Brazil. Acta Trop. 2008; 108: 242–244. S0001-706X(08)00207-6 [pii]. pmid:18722335
  151. 151. Noya O, Naftale K, Pointier JP, Theron A, Alarcón de Noya B. Schistosomiasis in America. In: Franco-Paredes C, Santos-Preciado JI, editors. Neglected Tropical Diseases in Latin America. Springer-Verlag Wien. 2015; pp. 11–43.
  152. 152. Holtfreter MC, Mone H, Muller-Stover I, Mouahid G, Richter J. Schistosoma haematobium infections acquired in Corsica, France, August 2013. Euro Surveill. 2014; 19.
  153. 153. Lambertucci JR, Drummond SC, Voieta I, de Queiroz LC, Pereira PP, Chaves BA, et al. An outbreak of acute Schistosoma mansoni Schistosomiasis in a nonendemic area of Brazil: a report on 50 cases, including 5 with severe clinical manifestations. Clin Infect Dis. 2013; 57: e1–e6. cit157 [pii]. pmid:23532472
  154. 154. Woelfle M, Seerden JP, de GJ, Pouwer K, Olliaro P, Todd MH. Resolution of praziquantel. PLoS Negl Trop Dis. 2011; 5: e1260. pmid:21949890
  155. 155. Garba A, Barkire N, Djibo A, Lamine MS, Sofo B, Gouvras AN, et al. Schistosomiasis in infants and preschool-aged children: Infection in a single Schistosoma haematobium and a mixed S. haematobium-S. mansoni foci of Niger. Acta Trop. 2010; 115: 212–219. S0001-706X(10)00083-5 [pii]. pmid:20303925
  156. 156. Stothard JR, Sousa-Figueiredo JC, Betson M, Green HK, Seto EY, Garba A. Closing the praziquantel treatment gap: new steps in epidemiological monitoring and control of schistosomiasis in African infants and preschool-aged children. Parasitology. 2011; 138: 1593–1606. S0031182011001235 [pii]. pmid:21861945